Long-term, open-label extension study of the efficacy and safety of epicutaneous immunotherapy for peanut allergy in children: PEOPLE 3-year results

• Published in: Journal of allergy and clinical immunology Vol. 146; no. 4; pp. 863 - 874
• Main Authors: Fleischer, David M., Shreffler, Wayne G., Campbell, Dianne E., Green, Todd D., Anvari, Sara, Assa’ad, Amal, Bégin, Philippe, Beyer, Kirsten, Bird, J. Andrew, Brown-Whitehorn, Terri, Byrne, Aideen, Chan, Edmond S., Cheema, Amarjit, Chinthrajah, Sharon, Chong, Hey Jin, Davis, Carla M., Ford, Lara S., Gagnon, Rémi, Greenhawt, Matthew, Hourihane, Jonathan O’B., Jones, Stacie M., Kim, Edwin H., Lange, Lars, Lanser, Bruce J., Leonard, Stephanie, Mahler, Vera, Maronna, Andreas, Nowak-Wegrzyn, Anna, Oriel, Roxanne C., O’Sullivan, Michael, Petroni, Daniel, Pongracic, Jacqueline A., Prescott, Susan L., Schneider, Lynda C., Smith, Peter, Staab, Doris, Sussman, Gordon, Wood, Robert, Yang, William H., Lambert, Romain, Peillon, Aurélie, Bois, Timothée, Sampson, Hugh A.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.10.2020
• Subjects: Administration, Cutaneous; Adolescent; Allergens - administration & dosage; Allergens - immunology; Biomarkers; Child; Child, Preschool; desensitization; Desensitization, Immunologic - adverse effects; Desensitization, Immunologic - methods; eliciting dose; epicutaneous immunotherapy; EPIT; Female; Follow-Up Studies; food allergy; Humans; Immunoglobulin E - immunology; immunotherapy; Male; Peanut allergy; Peanut Hypersensitivity - immunology; Peanut Hypersensitivity - therapy; sustained unresponsiveness; Treatment Outcome; PP; sIgE; SU; AE; HRQL; epicutaneous immunotherapy; IQR; food allergy; desensitization; mLOCF; eliciting dose; TEAE; CRD; Peanut allergy; EPIT; immunotherapy; sustained unresponsiveness; DBPCFC; ED

The PEPITES (Peanut EPIT Efficacy and Safety) trial, a 12-month randomized controlled study of children with peanut allergy and 4 to 11 years old, previously reported the safety and efficacy of epicutaneous immunotherapy (EPIT) for peanut allergy (250 μg, daily epicutaneous peanut protein; DBV712 25...